Zolpidem Use and Risk of Fracture in Elderly Insomnia Patients
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objectives: To evaluate the risk of fractures related with zolpidem in elderly insomnia patients. Methods: Health claims data on the entire South Korean elderly population from January 2005 to June 2006 were extracted from the Health Insurance Review and Assessment Service database. We applied a case-crossover design. Cases were defined as insomnia patients who had a fracture diagnosis. We set the hazard period of 1 day length prior to the fracture date and four control periods of the same length at 5, 10, 15, and 20 weeks prior to the fracture date. Time independent confounding factors such as age, gender, lifestyle,cognitive function level, mobility, socioeconomic status, residential environment, and comorbidity could be controlled using the casecrossover design. Time dependent confounding factors, especially co-medication of patients during the study period, were adjusted by conditional logistic regression analysis. The odds ratios and their 95% confidence intervals (CIs) were estimated for the risk of fracture related to zolpidem. Results: One thousand five hundred and eight cases of fracture were detected in insomnia patients during the study period. In our data, the use of zolpidem increased the risk of fracture significantly (adjusted odds ratio [aOR], 1.72; 95% CI, 1.37 to 2.16). However,the association between benzodiazepine hypnotics and the risk of fracture was not statistically significant (aOR, 1.00; 95% CI, 0.83 to 1.21). Likewise, the results were not statistically significant in stratified analysis with each benzodiazepine generic subgroup. Conclusions: Zolpidem could increase the risk of fracture in elderly insomnia patients. Therefore zolpidem should be prescribed carefully and the elderly should be provided with sufficient patient education.
Abstract
Objectives: To evaluate the risk of fractures related with zolpidem in elderly insomnia patients. Methods: Health claims data on the entire South Korean elderly population from January 2005 to June 2006 were extracted from the Health Insurance Review and Assessment Service database. We applied a case-crossover design. Cases were defined as insomnia patients who had a fracture diagnosis. We set the hazard period of 1 day length prior to the fracture date and four control periods of the same length at 5, 10, 15, and 20 weeks prior to the fracture date. Time independent confounding factors such as age, gender, lifestyle,cognitive function level, mobility, socioeconomic status, residential environment, and comorbidity could be controlled using the casecrossover design. Time dependent confounding factors, especially co-medication of patients during the study period, were adjusted by conditional logistic regression analysis. The odds ratios and their 95% confidence intervals (CIs) were estimated for the risk of fracture related to zolpidem. Results: One thousand five hundred and eight cases of fracture were detected in insomnia patients during the study period. In our data, the use of zolpidem increased the risk of fracture significantly (adjusted odds ratio [aOR], 1.72; 95% CI, 1.37 to 2.16). However,the association between benzodiazepine hypnotics and the risk of fracture was not statistically significant (aOR, 1.00; 95% CI, 0.83 to 1.21). Likewise, the results were not statistically significant in stratified analysis with each benzodiazepine generic subgroup. Conclusions: Zolpidem could increase the risk of fracture in elderly insomnia patients. Therefore zolpidem should be prescribed carefully and the elderly should be provided with sufficient patient education.
참고문헌 (40)
- Ohayon MM, "Prevalence of insomnia and associated factors in South Korea", J Psychosom Res, 53(1), pp.593~600 (2002)
- 조용원, "Epidemiology of Insomnia in Korean Adults: Prevalence and Associated Factors", Journal of Clinical Neurology, 5(1), pp.20~23 (2009), 대한신경과학회
- Jacobs GD, "Cognitive behavior therapy and pharmacotherapy for insomnia: a randomized controlled trial and direct comparison", Arch Intern Med, 164(17), pp.1888~1896 (2004)
- Korean NeuroPsychiatric Association, "Textbook of neuropsychiatry. 2nd ed", pp.670~682 (2005), Jungangmunhwa Co
- Stone KL, "Sleep, insomnia and falls in elderly patients", Sleep Med, 9(Suppl 1), pp.18~22 (2008)
- Maczaj M, "Pharmacological treatment of insomnia", Drugs, 45(1), pp.44~55 (1993)
- Richey SM, "Pharmacological advances in the treatment of insomnia", Curr Pharm Des, 17(15), pp.1471~1475 (2011)
- Lenhart SE, "Treatment of insomnia in hospitalized patients", Ann Pharmacother, 35(11), pp.1449~1457 (2001)
- Gustavsen I, "Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam", Sleep Med, 9(8), pp.818~822 (2008)
- King MB, "Is there still a role for benzodiazepines in general practice?", Br J Gen Pract, 42(358), pp.202~205 (1992)
- Langtry HD, "Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential", Drugs, 40(2), pp.291~313 (1990)
- Hoehns JD, "Zolpidem: a nonbenzodiazepine hypnotic for treatment of insomnia", Clin Pharm, 12(11), pp.814~828 (1993)
- Bogan RK, "Treatment options for insomnia: pharmacodynamics of zolpidem extended-release to benefit next-day performance", Postgrad Med, 120(3), pp.161~171 (2008)
- Hajak G, "Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16944 cases", Int Clin Psychopharmacol, 13(4), pp.157~167 (1998)
- Roth T, "Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo", Sleep, 18(4), pp.246~251 (1995)
- Maarek L, "The safety and efficacy of zolpidem in insomniac patients: a long-term open study in general practice", J Int Med Res, 20(2), pp.162~170 (1992)
- Allain H, "General safety profile of zolpidem: safety in elderly, overdose and rebound effects", Eur Psychiatry, 12(Suppl 1), pp.21~29 (1997)
- Lee YJ, "Overview of the therapeutic management of insomnia with zolpidem", CNS Drugs, 18(Suppl 1), pp.17~23 (2004)
- Vermeeren A, "Residual effects of hypnotics: epidemiology and clinical implications", CNS Drugs, 18(5), pp.297~328 (2004)
- Mendelson WB, "Sleepwalking associated with zolpidem", J Clin Psychopharmacol, 14(2), pp.150~ (1994)
- Iruela LM, "Zolpidem and sleepwalking", J Clin Psychopharmacol, 15(3), pp.223~ (1995)
- Hoque R, "Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18- flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem", J Clin Sleep Med, 5(5), pp.471~476 (2009)
- Yang W, "One rare side effect of zolpidem--sleepwalking: a case report", Arch Phys Med Rehabil, 86(6), pp.1265~1266 (2005)
- Buscemi N, "Manifestations and management of chronic insomnia in adults", Evid Rep Technol Assess (Summ), (125), pp.1~10 (2005)
- Zint K, "Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults", Pharmacoepidemiol Drug Saf, 19(12), pp.1248~1255 (2010)
- Glass J, "Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits", BMJ, 331(7526), pp.1169~ (2005)
- Wang PS, "Zolpidem use and hip fractures in older people", J Am Geriatr Soc, 49(12), pp.1685~1690 (2001)
- Antai-Otong D, "The art of prescribing. Risks and benefits of non-benzodiazepine receptor agonists in the treatment of acute primary insomnia in older adults", Perspect Psychiatr Care, 42(3), pp.196~200 (2006)
- Ki M, "Theory and practice of case-crossover study design", Korean J Epidemiol, 30(1), pp.1~11 (2008)
- Maclure M, "The case-crossover design: a method for studying transient effects on the risk of acute events", Am J Epidemiol, 133(2), pp.144~153 (1991)
- Maclure M, "‘Why me?’ versus ‘why now?’ Differences between operational hypotheses in case-control versus case-crossover studies", Pharmacoepidemiol Drug Saf, 16(8), pp.850~853 (2007)
- McMahon AD, "Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology", Pharmacoepidemiol Drug Saf, 7(4), pp.275~280 (1998)
- Tinetti ME, "Clinical practice. Preventing falls in elderly persons", N Engl J Med, 348(1), pp.42~49 (2003)
- Frost M, "Risk factors for fracture in elderly men: a population-based prospective study", Osteoporos Int, 23(2), pp.521~531 (2012)
- Hong GR, "Falls among Koreans 45 years of age and older: incidence and risk factors", J Adv Nurs, 66(9), pp.2014~2024 (2010)
- Chang CM, "Medical conditions and medications as risk factors of falls in the inpatient older people: a case-control study", Int J Geriatr Psychiatry, 26(6), pp.602~607 (2011)
- Vitry AI, "The risk of falls and fractures associated with persistent use of psychotropic medications in elderly people", Arch Gerontol Geriatr, 50(3), pp.1~4 (2010)
- Richey SM, "Pharmacological advances in the treatment of insomnia", Curr Pharm Des, 17(15), pp.1471~1475 (2011)
- Wagner J, "Beyond benzodiazepines: alternative pharmacologic agents for the treatment of insomnia", Ann Pharmacother, 32(6), pp.680~691 (1998)
- Ravera S, "Road traffic accidents and psychotropic medication use in The Netherlands: a case-control study", Br J Clin Pharmacol, 72(3), pp.505~513 (2011)